EMA validates application for Cabometyx for previously treated advanced HCC March 28, 2018 No Comments
EMA committee recommends approval of new dosing schedules for Opdivo in E.U. March 27, 2018 No Comments
EMA grants PRIME designation for lumasiran in primary hyperoxaluria type 1 March 27, 2018 No Comments
CHMP supports conditional marketing authorization for Clovis Oncology's Rubraca March 26, 2018 No Comments
RSS